Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Commercial Financing Research & Development

Personal Genome Diagnostics And Cleveland Diagnostics Will Use New Funding To Expand Cancer Portfolios

  • News

Executive Summary

Personal Genome Diagnostics will use its funding to expand its liquid biopsy portfolio. Cleveland Diagnostics plans to develop early detection tests for lung and breast cancer.

You may also be interested in...



Truvian Sciences Raises $105M Series C To Fund Development Of Point-Of-Care Testing Platform

Truvian Sciences will use the proceeds to fund regulatory submission for its POC testing system in Europe and the US with hopes to bring to retailers, pharmacies, health systems in 2022.

ReWalk Plans $40M Private Placement To Fund Marketing, R&D Of Exoskeletons

ReWalk plans to use the proceeds to fund sales, R&D and reimbursement expenses related to its ReStore and Personal 6.0 devices as it continues to face negative effects of pandemic.

Brainlab Receives FDA Clearance For Imaging Robot, Alignment Module For Spine

Brainlab is expanding its digital surgery portfolio with the FDA clearance for imaging and alignment module systems.

Table

View full table

Topics

Related Companies

Tags:
Commercial Financing Research & Development
UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By